On the heels of positive Phase 2 clinical trial data, Vir Biotechnology is planning for the 2025 launch of…
Articles by Lindsey Shapiro, PhD
About 45% of teens and adults in the U.S. have some form of fatty liver disease, with Hispanic populations…
Researchers have identified a possible mechanism by which infection with the hepatitis E virus (HEV), a known cause of…
The American Liver Foundation (ALF) has announced the eight winners of its 2024 Pilot Research Awards, with four of…
Precision Biosciences has opened a first-in-human trial testing its gene-editing therapy candidate PBGENE-HBV in people with chronic hepatitis…
The U.S. Food and Drug Administration (FDA) has cleared the launch of a Phase 1 drug-drug interaction study to evaluate…
Rectify Pharmaceuticals has selected the oral small molecule RTY-694 as its lead treatment candidate for primary sclerosing cholangitis…
Alterations to the immune system may underlie the mild liver scarring, or fibrosis, that characterizes Alagille syndrome despite severe…
Fewer than half of reproductive-aged women with opioid use disorder in the U.S. undergo hepatitis C testing, with Black…
The U.S. Food and Drug Administration (FDA) has designated Mirum Pharmaceuticals’ oral candidate volixibat a breakthrough therapy for…